Secretory Leukocyte Proteinase Inhibitor-Competent DNA Deposits Are Potent Stimulators of Plasmacytoid Dendritic Cells: Implication for Psoriasis

Journal of Immunology - Tập 189 Số 4 - Trang 1611-1617 - 2012
Joanna Skrzeczyńska-Moncznik1, Agnieszka Włodarczyk1, Katarzyna Zabieglo1, Monika Kapińska-Mrowiecka2, Ewa Marewicz1, Adam Dubin3, Jan Potempa4,5, Joanna Cichy1
1*Department of Immunology, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland;
2†Department of Dermatology, Zeromski Hospital, 31-913 Kraków, Poland;
3‡Department of Analytical Biochemistry, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland;
4§Department of Microbiology, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland; and
5¶School of Dentistry, University of Louisville, Louisville, KY 40202

Tóm tắt

Abstract

Secretory leukocyte proteinase inhibitor (SLPI) is a well-established inhibitor of serine proteases such as human neutrophil elastase (HNE) and a NF-κB regulatory agent in immune cells. In this paper, we report that SLPI plays a previously uncharacterized role in regulating activation of plasmacytoid dendritic cells (pDCs). As the main source of IFN type I (IFNI), pDCs are crucial contributors to inflammatory and likely wound-healing responses associated with psoriasis. The mechanisms responsible for activation of pDCs in psoriatic skin are therefore of substantial interest. We demonstrate that in lesional skin of psoriasis patients, SLPI together with its enzymatic target HNE and DNA, is a component of neutrophil extracellular traps (NETs). Whereas SLPI+ neutrophils and NETs were found to colocalize with pDCs in psoriatic skin, a mixture of SLPI with neutrophil DNA and HNE induced a marked production of IFNI by pDCs. IFNI synthesis by stimulated pDCs was dependent on intracellular DNA receptor TLR9. Thus, SLPI may contribute to psoriasis by enabling pDCs to sense extracellular DNA and produce IFNI.

Từ khóa


Tài liệu tham khảo

Doumas, 2005, Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor., Infect. Immun., 73, 1271, 10.1128/IAI.73.3.1271-1274.2005

Jacobsen, 2008, The secretory leukocyte protease inhibitor (SLPI) and the secondary granule protein lactoferrin are synthesized in myelocytes, colocalize in subcellular fractions of neutrophils, and are coreleased by activated neutrophils., J. Leukoc. Biol., 83, 1155, 10.1189/jlb.0706442

Jin, 1997, Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide., Cell, 88, 417, 10.1016/S0092-8674(00)81880-2

Sallenave, 1997, Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils., J. Leukoc. Biol., 61, 695, 10.1002/jlb.61.6.695

Wingens, 1998, Induction of SLPI (ALP/HUSI-I) in epidermal keratinocytes., J. Invest. Dermatol., 111, 996, 10.1046/j.1523-1747.1998.00425.x

Reardon, 2011, Thymic stromal lymphopoetin-induced expression of the endogenous inhibitory enzyme SLPI mediates recovery from colonic inflammation., Immunity, 35, 223, 10.1016/j.immuni.2011.05.015

Zhu, 2002, Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair., Cell, 111, 867, 10.1016/S0092-8674(02)01141-8

Taggart, 2005, Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding., J. Exp. Med., 202, 1659, 10.1084/jem.20050768

Xu, 2007, Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI., Nat. Immunol., 8, 294, 10.1038/ni1434

Subramaniyam, 2011, Secretory leukocyte protease inhibitor inhibits neutrophil apoptosis., Respirology, 16, 300, 10.1111/j.1440-1843.2010.01901.x

Remold-O’Donnell, 1989, Elastase inhibitor: characterization of the human elastase inhibitor molecule associated with monocytes, macrophages, and neutrophils., J. Exp. Med., 169, 1071, 10.1084/jem.169.3.1071

Faurschou, 2003, Neutrophil granules and secretory vesicles in inflammation., Microbes Infect., 5, 1317, 10.1016/j.micinf.2003.09.008

Fuchs, 2007, Novel cell death program leads to neutrophil extracellular traps., J. Cell Biol., 176, 231, 10.1083/jcb.200606027

Papayannopoulos, 2010, Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps., J. Cell Biol., 191, 677, 10.1083/jcb.201006052

Mantovani, 2011, Neutrophils in the activation and regulation of innate and adaptive immunity., Nat. Rev. Immunol., 11, 519, 10.1038/nri3024

Pinkus, 1966, The primary histologic lesion of seborrheic dermatitis and psoriasis., J. Invest. Dermatol., 46, 109, 10.1038/jid.1966.16

Garcia-Romo, 2011, Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus., Sci. Transl. Med., 3, 73ra20, 10.1126/scitranslmed.3001201

Hakkim, 2010, Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis., Proc. Natl. Acad. Sci. USA, 107, 9813, 10.1073/pnas.0909927107

Kessenbrock, 2009, Netting neutrophils in autoimmune small-vessel vasculitis., Nat. Med., 15, 623, 10.1038/nm.1959

Lande, 2011, Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus., Sci. Transl. Med., 3, 73ra19, 10.1126/scitranslmed.3001180

Lande, 2007, Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide., Nature, 449, 564, 10.1038/nature06116

Nestle, 2005, Plasmacytoid predendritic cells initiate psoriasis through interferon-α production., J. Exp. Med., 202, 135, 10.1084/jem.20050500

Blasius, 2010, Intracellular Toll-like receptors., Immunity, 32, 305, 10.1016/j.immuni.2010.03.012

Liu, 2005, IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors., Annu. Rev. Immunol., 23, 275, 10.1146/annurev.immunol.23.021704.115633

Sørensen, 1997, The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils., Blood, 90, 2796, 10.1182/blood.V90.7.2796

Sørensen, 2001, Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3., Blood, 97, 3951, 10.1182/blood.V97.12.3951

Baugh, 1976, Human leukocyte granule elastase: rapid isolation and characterization., Biochemistry, 15, 836, 10.1021/bi00649a017

Chase, 1970, Titration of trypsin, plasmin and trombin with p-nitrophenyl-pʹ-guanidinobenzoate HCl., Methods Enzymol., 19, 20, 10.1016/0076-6879(70)19004-5

Travis, 1983, Human plasma proteinase inhibitors., Annu. Rev. Biochem., 52, 655, 10.1146/annurev.bi.52.070183.003255

Boudier, 1994, Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor., Biochem. J., 303, 61, 10.1042/bj3030061

Nobar, 2005, Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3., FEBS J., 272, 5883, 10.1111/j.1742-4658.2005.04988.x

Sambrook, 1982, Molecular Cloning: A Laboratory Manual.

Lin, 2011, Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis., J. Immunol., 187, 490, 10.4049/jimmunol.1100123

Morgan, 1991, Cloning of the cDNA for the serine protease homolog CAP37/azurocidin, a microbicidal and chemotactic protein from human granulocytes., J. Immunol., 147, 3210, 10.4049/jimmunol.147.9.3210

Cichy, 1997, Biosynthesis of α1-proteinase inhibitor by human lung-derived epithelial cells., J. Biol. Chem., 272, 8250, 10.1074/jbc.272.13.8250

Gregorio, 2010, Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons., J. Exp. Med., 207, 2921, 10.1084/jem.20101102

Fäh, 1995, Expression of MxA protein in inflammatory dermatoses., J. Histochem. Cytochem., 43, 47, 10.1177/43.1.7822763

van der Fits, 2004, In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-α sensitivity is unaltered., J. Invest. Dermatol., 122, 51, 10.1046/j.0022-202X.2003.22113.x

Downs, 2000, Exacerbation of psoriasis by interferon-α therapy for hepatitis C., Clin. Exp. Dermatol., 25, 351, 10.1046/j.1365-2230.2000.00655-4.x

Ketikoglou, 2005, Extensive psoriasis induced by pegylated interferon α-2b treatment for chronic hepatitis B., Eur. J. Dermatol., 15, 107

Ashcroft, 2000, Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing., Nat. Med., 6, 1147, 10.1038/80489